Clinical trial
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating…
NCT00047294 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00047294 |
|---|---|
| Title | Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| Official title | Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Procedure |
| Interventions | celecoxib, temozolomide, thalidomide, adjuvant therapy |
| Start date | Apr 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: